D-Y-L Chang-Chan1, R Ríos-Tamayo2,3,4,5, M Rodríguez Barranco1,6,7, D Redondo-Sánchez1,6,7, Y González8, R Marcos-Gragera6,9,10,11, M J Sánchez1,6,7,12. 1. Granada Cancer Registry, Andalusian School of Public Health, Granada, Spain. 2. Monoclonal Gammopathies Clinical Trials Unit, Department of Hematology, University Hospital Virgen de Las Nieves, Granada, Spain. rriost33@gmail.com. 3. Genomic Oncology Area, GENYO, PTS, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain. rriost33@gmail.com. 4. Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. rriost33@gmail.com. 5. Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. rriost33@gmail.com. 6. Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 7. Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 8. Department of Hematology, Catalan Institute of Oncology, Josep Trueta University Hospital, Girona, Spain. 9. Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain. 10. Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain. 11. Josep Carreras Leukemia Research Institute, Girona, Spain. 12. Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain.
Abstract
BACKGROUND: Despite major advances, multiple myeloma remains an incurable disease. Epidemiological data from high-quality population-based registries are needed to understand the heterogeneous landscape of the disease. METHODS: Incidence, mortality and survival in multiple myeloma were comprehensively analyzed in the Girona and Granada population-based cancer registries, over a 23-year study (1994-2016), divided into three periods (1994-2001, 2002-2009 and 2010-2016). Joinpoint regression analysis was used to estimate the annual percentage change in incidence and mortality. Age-standardized net survival was calculated with the Pohar-Perme method. RESULTS: 1957 myeloma patients were included in the study, with a median age of 72 years. Age-standardized incidence and mortality rates decreased over time in both sexes and both rates were higher in males. Five-year age-standardized net survival by period was 27.4% (1994-2001), 38.8% (2002-2009), and 47.4% (2010-2016). Survival improved for all age groups: 32.4%, 74.1% and 78.5% for patients aged 15-49; 27.5%, 44.6%, and 58.5% for those aged 50-69; finally, 24.8%, 25.5%, and 26.3% for the older group. CONCLUSION: Incidence remained overall stable throughout the study, with only a small increase for men. Mortality was progressively decreasing in both sexes. Both incidence and mortality were higher in men. Age plays a critical role in survival, with impressive improvement in patients younger than 70 years, but only a minor benefit in those older than 70.
BACKGROUND: Despite major advances, multiple myeloma remains an incurable disease. Epidemiological data from high-quality population-based registries are needed to understand the heterogeneous landscape of the disease. METHODS: Incidence, mortality and survival in multiple myeloma were comprehensively analyzed in the Girona and Granada population-based cancer registries, over a 23-year study (1994-2016), divided into three periods (1994-2001, 2002-2009 and 2010-2016). Joinpoint regression analysis was used to estimate the annual percentage change in incidence and mortality. Age-standardized net survival was calculated with the Pohar-Perme method. RESULTS: 1957 myeloma patients were included in the study, with a median age of 72 years. Age-standardized incidence and mortality rates decreased over time in both sexes and both rates were higher in males. Five-year age-standardized net survival by period was 27.4% (1994-2001), 38.8% (2002-2009), and 47.4% (2010-2016). Survival improved for all age groups: 32.4%, 74.1% and 78.5% for patients aged 15-49; 27.5%, 44.6%, and 58.5% for those aged 50-69; finally, 24.8%, 25.5%, and 26.3% for the older group. CONCLUSION: Incidence remained overall stable throughout the study, with only a small increase for men. Mortality was progressively decreasing in both sexes. Both incidence and mortality were higher in men. Age plays a critical role in survival, with impressive improvement in patients younger than 70 years, but only a minor benefit in those older than 70.
Authors: Rafael Ríos-Tamayo; María José Sánchez; José Manuel Puerta; Juan Sáinz; Daysi-Yoe-Ling Chang; Teresa Rodríguez; Pilar López; José María de Pablos; Pilar Navarro; José Luís García de Veas; Antonio Romero; Pilar Garrido; Lucía Moratalla; Carolina Alarcón-Payer; Elisa López-Fernández; Pedro Antonio González; José Juan Jiménez-Moleón; Miguel Ángel Calleja-Hernández; Manuel Jurado Journal: Cancer Epidemiol Date: 2015-08-12 Impact factor: 2.984
Authors: J Galceran; A Ameijide; M Carulla; A Mateos; J R Quirós; D Rojas; A Alemán; A Torrella; M Chico; M Vicente; J M Díaz; N Larrañaga; R Marcos-Gragera; M J Sánchez; J Perucha; P Franch; C Navarro; E Ardanaz; J Bigorra; P Rodrigo; R Peris Bonet Journal: Clin Transl Oncol Date: 2017-01-16 Impact factor: 3.405
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel Journal: Lancet Oncol Date: 2014-10-26 Impact factor: 41.316
Authors: Alicia Villavicencio; Marta Solans; Carmen Auñon-Sanz; Josep Maria Roncero; Rafael Marcos-Gragera Journal: Cancer Epidemiol Date: 2020-11-04 Impact factor: 2.984
Authors: Rafael Ríos-Tamayo; Juan Sáinz; Joaquín Martínez-López; José Manuel Puerta; Daysi-Yoe-Ling Chang; Teresa Rodríguez; Pilar Garrido; José Luís García de Veas; Antonio Romero; Lucía Moratalla; Elisa López-Fernández; Pedro Antonio González; María José Sánchez; José Juan Jiménez-Moleón; Manuel Jurado; Juan José Lahuerta Journal: Am J Hematol Date: 2016-04-28 Impact factor: 10.047